Medical therapy options for aging men with benign prostatic hyperplasia: Focus on alfuzosin 10 mg once daily

Claus Roehrborn, Raymond C. Rosen

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations

Abstract

Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) are common in aging men and can significantly affect quality of life. Men with bothersome LUTS/BPH often present with various other age-related conditions, including sexual dysfunction, heart disease, hypertension, diabetes, and the metabolic syndrome, which can complicate management decisions. Therefore, healthcare providers should be familiar with first-line treatment options for LUTS/BPH and their differing safety profiles, particularly with respect to cardiovascular and sexual function side effects. This article presents a review of first-line medical therapy options for managing aging men with LUTS/BPH and patient considerations when evaluating and selecting these therapies, with a focus on the clinical efficacy and cardiovascular and sexual function safety profiles of the uroselective α1-adrenergic receptor antagonist alfuzosin 10 mg once daily. Alfuzosin improves LUTS, peak urinary flow rates, and disease-specific quality of life, reduces the long-term risk of overall BPH progression, and is well tolerated in aging men, with minimal vasodilatory and sexual function side effects, even in those with comorbidities. Alfuzosin is well tolerated when used in combination with antihypertensive medications and phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. The long-term clinical efficacy and good cardiovascular and sexual function safety profile of alfuzosin can contribute to an improved quality of life for aging men with LUTS/BPH.

Original languageEnglish (US)
Pages (from-to)511-524
Number of pages14
JournalClinical interventions in aging
Volume3
Issue number3
StatePublished - Nov 4 2008

Keywords

  • Aging
  • Alfuzosin
  • Benign prostatic hyperplasia
  • Cardiovascular system
  • Lower urinary tract symptoms
  • Sexual function

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Medical therapy options for aging men with benign prostatic hyperplasia: Focus on alfuzosin 10 mg once daily'. Together they form a unique fingerprint.

Cite this